DOCSLIB.ORG

IBS-Monograph-2018.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IBS-Monograph-2018.Pdf SUPPLEMENT 1 see related editorial on page x American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome Alexander C. Ford, MB ChB, MD, FRCP1, Paul Moayyedi, BSc, MB ChB, PhD, MPH, FACG, FRCP, FRCPC, AGAF2, William D. Chey, MD, FACG, AGAF, FACP3, Lucinda A. Harris, MD, FACG4, Brian E. Lacy, MD, PhD, FACG5, Yuri A. Saito, MD, MPH, FACG6 and Eamonn M. M. Quigley, MD, MACG, FRCP, FACP, FRCPI7 for the ACG Task Force on Management of Irritable Bowel Syndrome Am J Gastroenterol https://doi.org/10.1038/s41395-018-0084-x INTRODUCTION IBS assumes considerable importance, therefore, not just for the Irritable bowel syndrome (IBS) is the most prevalent of the func- individual suferer, but for society at large. tional gastrointestinal disorders (FGIDs). Current estimates are Given the clinical heterogeneity that is a hallmark of the disor- that IBS afects up to 10–12% of adults in North America [1, 2]. der and the absence of a single efective therapy for all suferers, Although it can afect all individuals regardless of age, creed, or available therapies tend to focus on predominant symptomatol- gender, IBS is more common among women and is most com- ogy at presentation (i.e., altered bowel habits, abdominal pain, or monly diagnosed in younger individuals (<age 50) [2, 3]. IBS bloating) [4–6]. Based on their purported mode of action, many is characterized by recurrent abdominal pain and altered bowel pharmacological therapies for IBS developed in recent decades habits; bloating and distention frequently coexist. Te diagnosis have been directed towards those with a particular bowel habit, of IBS is made by taking a careful history, eliciting key symptoms, whether diarrhea or constipation. However, treating IBS patients as well as performing a physical examination and limited diagnos- can be difcult as no validated treatment algorithm exists, not all tic testing [4–6]. IBS is categorized into four main subtypes based patients respond to treatment, and patients with similar symptoms on the predominant bowel habit: IBS with constipation (IBC-C); frequently respond to the same treatment diferently. Fortunately, IBS with diarrhea (IBS-D); IBS with mixed symptomology (IBS- a variety of novel therapeutic strategies are being explored and M); and unclassifed IBS [5]. new compounds have appeared since the last iteration of the ACG IBS imposes a signifcant burden to the health care system and monograph on IBS [4]. Te goal of this document, therefore, is to to individuals. Direct medical costs attributed to IBS in the US, provide an updated, evidence-based document on the therapy of excluding prescription and over-the-counter medicines, were this common and, at times, debilitating disorder. estimated at $1.5–$10 billion per year in 2005 [7]. Patients with IBS enrolled in a large Health Maintenance Organization (HMO) had signifcantly more outpatient visits and incurred nearly 50% AN OVERVIEW OF METHODOLOGY FOR SYSTEMATIC more in total costs than individuals without IBS [8]. A retrospec- REVIEWS OF IBS THERAPY tive case-control study from another large HMO reported that Prior to the last evidence-based systematic review on the manage- patients with IBS had signifcantly more diagnostic tests, imaging, ment of irritable bowel syndrome commissioned and published and surgery compared with patients without a diagnosis of IBS [9]. by the ACG in 2014 [4], and the work that underpinned this, there Signifcant variations in care across the United States related to the had been several systematic reviews of available therapies for IBS diagnosis and treatment of IBS also play a role in excessive health [13–22]. We have previously shown that these had either not syn- care costs [10]. Te burden of IBS on individuals can be measured thesized the data correctly, or contained inaccuracies in applying in a number of ways. Studies have demonstrated consistently that eligibility criteria and data extraction [23]. We have, therefore, IBS impairs work-related activities (e.g., lost work time, reduced updated all the rigorously performed meta-analyses [24–27], productivity while at work) and also reduces quality of life [11, 12]. which informed the ACG position statement in 2014, according Te development of efective and efcient treatment strategies for to the following protocol: 1Leeds Institute of Biomedical and Clinical Sciences, University of Leeds and Leeds Gastroenterology Institute, Leeds Teaching Hospitals Trust, Leeds, UK. 2Division of Gastroenterology, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada. 3Division of Gastroenterology, Department of Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA. 4Mayo Clinic, Scottsdale, AZ, USA. 5Mayo Clinic, Jacksonville, FL, USA. 6Mayo Clinic, Rochester, MN, USA. 7Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA. Correspondence: E.M.M.Q. (email: [email protected]) © 2018 The American College of Gastroenterology The American Journal of GASTROENTEROLOGY 2 Ford et al. Objectives heading (MeSH) and free text terms), and IBS, spastic colon, irrita- Primary outcome. To assess the efcacy of available pharmaco- ble colon, and functional adj5 bowel (as free text terms). logical therapies in treating IBS compared with placebo, or, in the For RCTs of dietary manipulation these were combined using case of psychological and dietary therapies, in comparison with the set operator AND with studies identifed with the terms: diet, either no treatment or standard/usual care. fat-restricted, diet, protein-restricted, diet, carbohydrate-restricted, diet, gluten-free, diet, macrobiotic, diet, vegetarian, diet, Mediterra- Secondary outcomes. To assess the efcacy of available phar- nean, diet fads, gluten, lactose intolerance, or lactose (both as MeSH macological, psychological, and dietary therapies in treating IBS terms and free text terms), or the following free text terms: FOD- according to predominant stool pattern reported (IBS-C, IBS-D, MAP$, glutens, or food adj5 intolerance. or IBS-M), and to assess adverse events with pharmacological and For RCTs of fber, antispasmodics, and peppermint oil these other therapies for IBS. were combined using the set operator AND with studies identi- fed with the terms: dietary fber, cereals, psyllium, sterculia, karaya Criteria for considering studies for this review gum, parasympatholytics, scopolamine, trimebutine, muscarinic Types of studies. Only parallel-group randomized controlled trials antagonists, or butylscopolammonium bromide (both as MeSH and (RCTs) comparing pharmacological therapies with placebo, or com- free text terms), or the following free text terms: bulking agent, paring psychological and dietary therapies with either no treatment psyllium fber, fber, husk, bran, ispaghula, wheat bran, spasmolyt- or standard/usual care, were considered for this review. Cross-over ics, spasmolytic agents, antispasmodics, mebeverine, alverine, pinav- trials were eligible for inclusion, provided extractable data were pro- erium bromide, otilonium bromide, cimetropium bromide, hyoscine vided at the end of the frst treatment period, prior to cross-over. butyl bromide, butylscopolamine, drotaverine, peppermint oil, or colpermin. Types of participants. Adults over 16 years of age recruited from For RCTs of prebiotics, synbiotics, probiotics, and antibiotics primary, secondary, or tertiary care with IBS symptoms diagnosed these were combined using the set operator AND with studies by any criteria (including clinical impression). identifed with the terms: Saccharomyces, Lactobacillus, Bifdo- bacterium, Escherichia coli, probiotics, prebiotics, synbiotics, anti- Types of interventions. Te following treatments were consid- bacterial agents, penicillins, cephalosporins, rifamycins, quinolones, ered eligible: nitroimidazoles, tetracycline, doxycycline, amoxicillin, ciprofoxacin, metronidazole, or tinidazole (both as MeSH and free text terms), or 1. Exercise, diet, and dietary manipulation the following free text terms: antibiotic, or rifaximin. 2. Fiber For RCTs of antidepressants and psychological therapies, 3. Interventions that modify the microbiota: prebiotics, synbiot- including hypnotherapy, these were combined using the set opera- ics, probiotics, and antibiotics tor AND with studies identifed with the terms: psychotropic drugs, 4. Antispasmodics and peppermint oil antidepressive agents, antidepressive agents (tricyclic), desipra- 5. Antidepressants mine, imipramine, trimipramine, doxepin, dothiepin, nortriptyline, 6. Psychological interventions amitriptyline, selective serotonin re-uptake inhibitors, paroxetine, 7. Pro-secretory agents: linaclotide, plecanatide, and lubiprostone sertraline, fuoxetine, citalopram, venlafaxine, cognitive therapy, 8. Eluxadoline psychotherapy, behavior therapy, relaxation techniques, or hypnosis 9. Loperamide (both as MeSH terms and free text terms), or the following free 10. Serotonergic agents text terms: behavioral therapy, relaxation therapy, or hypnotherapy. 11. Polyethylene glycol For RCTs of linaclotide, plecanatide, lubiprostone, eluxadoline, 12. 5-aminosalicylates and loperamide these were combined using the set operator AND with studies identifed with the terms loperamide or antidiarrheals Types of outcome measures. Subjects needed to be followed up (both as MeSH and free text terms), as well as the following for at least 1 week. Te trials needed to include one or more of the free text
Load more

Recommended publications
  • Gastrointestinal (GI) Motility, Chronic Therapeutic Class Review
    Gastrointestinal (GI) Motility, Chronic Therapeutic Class Review (TCR) March 7, 2019 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. March 2019 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004–2019 Magellan Rx Management. All Rights Reserved. FDA-APPROVED INDICATIONS Drug Manufacturer Indication(s) alosetron (Lotronex®)1 generic, .
    [Show full text]
  • List of Covered Drugs
    List of Covered Drugs Effective July 1, 2016 INTRODUCTION We are pleased to provide the 2011 Gold Coast Health Plan List of Covered Drugs as a useful reference and informational tool. The GCHP List of Covered Drugs can assist practitioners in selecting clinically appropriate and cost effective products for their patients. The information contained in the GCHP List of Covered Drugs is provided solely for the convenience of medical providers. We do not warrant or assure accuracy of such information nor is it intended to be comprehensive in nature. This List of Covered Drugs is not intended to be a substitute for the knowledge, expertise, skill and judgment of the medical provider in his or her choice of prescription drugs. All the information in this List of Covered Drugs is provided as a reference for drug therapy selection. Specific drug selection for an individual patient rests solely with the prescriber. We assume no responsibility for the actions or omissions of any medical provider based upon reliance, in whole or in part, on the information contained herein. The medical provider should consult the drug manufacturer's product literature or standard references for more detailed information. National guidelines can be found on the National Guideline Clearinghouse site at http://www.guideline.gov PREFACE The GCHP List of Covered Drugs is organized by sections. Each section is divided by therapeutic drug class primarily defined by mechanism of action. Unless exceptions are noted, generally all applicable dosage forms and strengths of the drug cited are included in the GCHP List of Covered Drugs. Generics should be considered the first line of prescribing.
    [Show full text]
  • Inflammatory Bowel Disease Irritable Bowel Syndrome
    Inflammatory Bowel Disease and Irritable Bowel Syndrome Similarities and Differences 2 www.ccfa.org IBD Help Center: 888.MY.GUT.PAIN 888.694.8872 Important Differences Between IBD and IBS Many diseases and conditions can affect the gastrointestinal (GI) tract, which is part of the digestive system and includes the esophagus, stomach, small intestine and large intestine. These diseases and conditions include inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). IBD Help Center: 888.MY.GUT.PAIN 888.694.8872 www.ccfa.org 3 Inflammatory bowel diseases are a group of inflammatory conditions in which the body’s own immune system attacks parts of the digestive system. Inflammatory Bowel Disease Inflammatory bowel diseases are a group of inflamma- Causes tory conditions in which the body’s own immune system attacks parts of the digestive system. The two most com- The exact cause of IBD remains unknown. Researchers mon inflammatory bowel diseases are Crohn’s disease believe that a combination of four factors lead to IBD: a (CD) and ulcerative colitis (UC). IBD affects as many as 1.4 genetic component, an environmental trigger, an imbal- million Americans, most of whom are diagnosed before ance of intestinal bacteria and an inappropriate reaction age 35. There is no cure for IBD but there are treatments to from the immune system. Immune cells normally protect reduce and control the symptoms of the disease. the body from infection, but in people with IBD, the immune system mistakes harmless substances in the CD and UC cause chronic inflammation of the GI tract. CD intestine for foreign substances and launches an attack, can affect any part of the GI tract, but frequently affects the resulting in inflammation.
    [Show full text]
  • Isopropamide Iodide
    www.chemicalland21.com ISOPROPAMIDE IODIDE SYNONYMS (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; 2,2-Diphenyl-4- diisopropylaminobutyramide methiodide; 4-(Diisopropylamino)-2,2-diphenylbutyramide methiodide; gamma-(Aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-gamma-phenylbenzenepropanaminium iodide; Iodure d'isopropamide; Ioduro de isopropamida; Isopropamide ioduro; Isopropamidi iodidum; Isoproponum iodide; PRODUCT IDENTIFICATION CAS RN 71-81-8 EINECS RN 200-766-8 FORMULA C23H33IN2O MOL WEIGHT 480.43 PHYSICAL AND CHEMICAL PROPERTIES PHYSICAL STATE white to off-white powder MELTING POINT 199 C BOILING POINT DENSITY SOLUBILITY IN WATER pH VAPOR DENSITY REFRACTIVE INDEX FLASH POINT GENERAL DESCRIPTION Isopropamide is a long-acting anticholinergic and antimuscarinic drug of quaternary ammonium structure. It is used in the form of the iodide, (also bromide or chloride) to treat peptic ulcer and to suppress gastric secretion other gastrointestinal disorders. Brands of Isopropamide drugs: Darbid Dipramide Isamide Marygin-M Piaccamide Priamide Priazimide Sanulcin Tyrimide Quaternary ammonium anticholinergics (Synthetic) ATC Code Product CAS RN. A03AB01 Benzilonium bromide 1050-48-2 A03AB02 Glycopyrrolate 596-51-0 A03AB03 Oxyphenonium 14214-84-7 A03AB04 Penthienate 22064-27-3 A03AB05 Propantheline 50-34-0 A03AB06 Otilonium bromide 26095-59-0 A03AB07 Methantheline 5818-17-7 Please mail us if you want to sell your product or need to buy some products) www.chemicalland21.com ISOPROPAMIDE IODIDE A03AB08 Tridihexethyl 60-49-1 A03AB09 Isopropamide 7492-32-2 A03AB10 Hexocyclium 6004-98-4 A03AB11 Poldine 596-50-9 A03AB12 Mepenzolic acid 25990-43-6 A03AB13 Bevonium 33371-53-8 A03AB14 Pipenzolate 13473-38-6 A03AB15 Diphemanil methylsulfate 62-97-5 A03AB16 (2-Benzhydryloxyethyl)diethyl-methylammonium iodide A03AB17 Tiemonium iodide 144-12-7 A03AB18 Prifinium bromide 4630-95-9 A03AB19 Timepidium bromide 35035-05-3 A03AB21 Fenpiverinium bromide 125-60-0 03AB53 Oxyphenonium, combinations STABILITY AND REACTIVITY STABILITY Stable under normal conditions.
    [Show full text]
  • Eluxadoline: a Treatment for IBS with Diarrhoea in Adults
    ■ NEW PRODUCT Eluxadoline: a treatment for IBS with diarrhoea in adults STEVE CHAPLIN Eluxadoline (Truberzi) KEY POINTS is an oral mixed opioid- receptor agonist/ ■ Eluxadoline is an opioid-receptor agonist/antagonist with low systemic absorption antagonist licensed for ■ It is licensed for the treatment of irritable bowel syndrome with diarrhoea in the treatment of irritable adults and is recommended by NICE as a second-line agent bowel syndrome with ■ The recommended dosage is 75–100mg orally twice daily diarrhoea in adults. ■ In clinical trials, response rates were 27%–31% with eluxadoline and 19.5% with placebo after 26 weeks’ treatment This article examines its ■ Common adverse effects include constipation, nausea and abdominal pain properties, efficacy in ■ Pancreatitis and sphincter of Oddi spasm were uncommon adverse events clinical trials and side- ■ Treatment with eluxadoline costs £88.20 per month. effects. he initial management of irritable locally within the gastrointestinal tract, Tbowel syndrome (IBS) entails dietary slowing gastrointestinal transit, reducing and lifestyle change and treatment with urgency and improving stool consistency; antispasmodic agents.1 For people with its abuse potential is low. IBS and diarrhoea, loperamide is the anti- Eluxadoline is licensed for the treat- motility agent of first choice, adjusting the ment of IBS with diarrhoea in adults. The dose to achieve optimum stool consist- recommended dosage is 100mg twice ency. If this is unsatisfactory, treatment daily (reduced to 75mg twice daily if with a low-dose tricyclic antidepressant poorly tolerated). Treatment should be should be considered, with an SSRI a initiated at the lower dose in older people further option if this is unsuccessful.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • FDA Warns About an Increased Risk of Serious Pancreatitis with Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder
    FDA warns about an increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder Safety Announcement [03-15-2017] The U.S. Food and Drug Administration (FDA) is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, we are working with the Viberzi manufacturer, Allergan, to address these safety concerns. Patients should talk to your health care professional about how to control your symptoms of irritable bowel syndrome with diarrhea (IBS-D), particularly if you do not have a gallbladder. The gallbladder is an organ that stores bile, one of the body’s digestive juices that helps in the digestion of fat. Stop taking Viberzi right away and get emergency medical care if you develop new or worsening stomach-area or abdomen pain, or pain in the upper right side of your stomach-area or abdomen that may move to your back or shoulder. This pain may occur with nausea and vomiting. These may be symptoms of pancreatitis, an inflammation of the pancreas, an organ important in digestion; or spasm of the sphincter of Oddi, a muscular valve in the small intestine that controls the flow of digestive juices to the gut. Health care professionals should not prescribe Viberzi in patients who do not have a gallbladder and should consider alternative treatment options in these patients.
    [Show full text]
  • WO 2010/015655 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 11 February 2010 (11.02.2010) WO 2010/015655 Al (51) International Patent Classification: sham Research Centre, Wimblehurst Road, Horsham C07C 233/79 (2006.01) C07D 277/42 (2006.01) West Sussex RH 12 5AB (GB). SVIRIDENKO, Lilya C07C 255/58 (2006.01) A61K 31/166 (2006.01) [GB/GB]; Novartis Horsham Research Centre, Wimble C07C 311/39 (2006.01) A61K 31/427 (2006.01) hurst Road, Horsham West Sussex RH 12 5AB (GB). C07D 213/74 (2006.01) A61K 31/44 (2006.01) (74) Agent: VOEGELI-LANGE, Regina; Novartis Pharma C07D 213/75 (2006.01) A61P 1/00 (2006.01) Ag, Patent Department, CH-4002 Basel (CH). C07D 213/84' (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/EP2009/060150 AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 5 August 2009 (05.08.2009) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (25) Filing Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (30) Priority Data: SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, 08162006.4 7 August 2008 (07.08.2008) EP TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Therapeutic Class Overview Irritable Bowel Syndrome Agents
    Therapeutic Class Overview Irritable Bowel Syndrome Agents Therapeutic Class Overview/Summary: This review will focus on agents used for the treatment of Irritable Bowel Syndrome (IBS).1-5 IBS is a gastrointestinal syndrome characterized primarily by non-specific chronic abdominal pain, usually described as a cramp-like sensation, and abnormal bowel habits, either constipation or diarrhea, in which there is no organic cause. Other common gastrointestinal symptoms may include gastroesophageal reflux, dysphagia, early satiety, intermittent dyspepsia and nausea. Patients may also experience a wide range of non-gastrointestinal symptoms. Some notable examples include sexual dysfunction, dysmenorrhea, dyspareunia, increased urinary frequency/urgency and fibromyalgia-like symptoms.6 IBS is defined by one of four subtypes. IBS with constipation (IBS-C) is the presence of hard or lumpy stools with ≥25% of bowel movements and loose or watery stools with <25% of bowel movements. When IBS is associated with diarrhea (IBS-D) loose or watery stools are present with ≥25% of bowel movements and hard or lumpy stools are present with <25% of bowel movements. Mixed IBS (IBS-M) is defined as the presence of hard or lumpy stools with ≥25% and loose or water stools with ≥25% of bowel movements. Final subtype, or unsubtyped, is all other cases of IBS that do not fall into the other classes. Pharmacological therapy for IBS depends on subtype.7 While several over-the-counter or off-label prescription agents are used for the treatment of IBS, there are currently only two agents approved by the Food and Drug Administration (FDA) for the treatment of IBS-C and three agents approved by the FDA for IBS-D.
    [Show full text]
  • Prophylactic Antiemetic Therapy with Ondansetron, Granisetron and Metoclopramide in Patients Undergoing Laparoscopic Cholecystectomy Under GA
    JK SCIENCE ORIGINAL ARTICLE Prophylactic Antiemetic Therapy with Ondansetron, Granisetron and Metoclopramide in Patients Undergoing Laparoscopic Cholecystectomy Under GA Vishal Gupta, Renu Wakhloo, Anjali Mehta, Satya Dev Gupta Abstract The aim of the present study was to compare the antiemetic effect of intravenous Granisetron, Ondansetron & Metoclopramide in a randomized blinded study for prophylaxis of post operative nausea and vomiting (PONV) in patients undergoing laparoscopic cholecystectomy under general anaesthesia. 60 patients (ASA I & II) undergoing laparoscopic cholecystectomy under general anaesthesia were randomly allocated into three equal groups (n=20). Emetic episodes in first 24 hours were recorded and compared in different study groups. Results were analyzed. Minimal emetic episodes were observed in early post-operative period (1-12hrs) in patients who had received intravenous granisetron in comparison to ondansetron and metoclopramide. However, after 12 hours emesis free periods were statistically insignificant between group A and B while patients in group C had no antiemetic effect. Keywords Post Operative Nausea and Vomiting (PONV), Granisetron, Ondensetron, Metoclopramide Introduction The most common and distressing symptoms, which vascular anastomoses and increased intracranial follow anaesthesia and surgery, are pain and emesis. The pressure(4). The anaesthetic consequences are aspiration syndrome of nausea, retching and vomiting is known as pneumonitis and discomfort in recovery. For institutions 'sickness' and each part of it can be distinguished as a there is increased financial burden because of increased separate entity (1). PONV (post operative nausea and nursing care, delayed discharge from Phase I and II vomiting) has been characterized as big 'little problem(2) recovery units and unexpected admissions. Hence, and has been a common complication for both in patients prophylactic antiemetic therapy is needed for all these and out patients undergoing virtually all types of surgical patients.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • Comprehensive Pgx Report for 1 / 31 Examples of Different Levels of Evidence for Pgx Snps
    Comprehensive PGx report for PERSONAL DETAILS Advanced Diagnostics Laboratory LLC CLIA:31D2149403 Phone: Fax: PATIENT DOB Address: 1030 North Kings Highway Suite 304 Cherry Hill, NJ 08034 GENDER FEMALE Website: http://advanceddiagnosticslaboratory.com/ SPECIMEN TYPE Oral Fluid LABORATORY INFORMATION ORDERING PHYSICIAN ACCESSION NUMBER 100344 FACILITY COLLECTION DATE 08/10/2020 RECEIVED DATE 08/14/2020 REPORT GENERATED 09/08/2020 LABORATORY DIRECTOR Dr. Jeanine Chiaffarano Current Patient Medication Clonidine (Catapres, Kapvay) The personalized pharmacogenomics profile of this patient reveals intermediate CYP2D6-mediated metabolism, extensive CYP1A2-mediated metabolism, and extensive CYP3A5-mediated metabolism. For further details, please find supporting evidence in this report or on websites such as www.pharmgkb.org or www.fda.gov. Losartan (Cozaar) The personalized pharmacogenomics profile of this patient reveals extensive CYP2C9-mediated metabolism, extensive CYP3A4-mediated metabolism, and extensive CYP3A5-mediated metabolism. For further details, please find supporting evidence in this report or on websites such as www.pharmgkb.org or www.fda.gov. Diltiazem (Cardizem, Tiazac) The personalized pharmacogenomics profile of this patient reveals extensive CYP3A4-mediated metabolism, intermediate CYP2C19-mediated metabolism, and extensive CYP3A5- mediated metabolism. For further details, please find supporting evidence in this report or on websites such as www.pharmgkb.org or www.fda.gov. Labetalol (Normodyne, Trandate) The personalized pharmacogenomics profile of this patient reveals intermediate CYP2D6-mediated metabolism, and intermediate CYP2C19-mediated metabolism. For further details, please find supporting evidence in this report or on websites such as www.pharmgkb.org or www.fda.gov. Mycophenolate mofetil (Myfortic, CellCept) The personalized pharmacogenomics profile of this patient reveals extensive CYP3A4-mediated metabolism, extensive CYP3A5-mediated metabolism, and extensive CYP2C8-mediated metabolism.
    [Show full text]